©NIJRMS
Publications 2025

OPEN ACCESS
ONLINE ISSN: 2992-5460
PRINT ISSN: 2992-6041

NEWPORT INTERNATIONAL JOURNAL OF RESEARCH IN MEDICAL SCIENCES (NIJRMS)

Volume 6 Issue 2 Page 11-14 2025

https://doi.org/10.59298/NIJRMS/2025/6.2.1114

Congenital Defects in the Immune System: A Pathway to Personalized Immunotherapy

Nakaziya Obutuzi G.

Faculty of Medicine Kampala International University Uganda

ABSTRACT

Congenital defects in the immune system, collectively known as primary immunodeficiency disorders (PIDs), present significant clinical challenges due to their impact on host defense mechanisms. These disorders result from genetic mutations affecting various components of the innate and adaptive immune systems, leading to recurrent infections, autoimmunity, and increased susceptibility to malignancies. Recent advancements in immunogenetics and precision medicine have paved the way for personalized immunotherapy approaches tailored to individual immune defects. This review explores the pathophysiology of congenital immune deficiencies, diagnostic strategies, and the evolving landscape of targeted immunotherapeutic interventions, including gene therapy, monoclonal antibodies, cytokine modulation, and hematopoietic stem cell transplantation (HSCT). Personalized immunotherapy holds promise for improving patient outcomes by addressing specific genetic and molecular abnormalities underlying immune dysfunction.

Keywords: Primary immunodeficiency disorders, personalized immunotherapy, gene therapy, monoclonal antibodies, cytokine modulation, hematopoietic stem cell transplantation

INTRODUCTION

Primary immunodeficiency disorders (PIDs) comprise a diverse group of congenital defects in the immune system, leading to impaired immune function [1]. These disorders manifest as recurrent infections, autoimmune conditions, and an elevated risk of malignancies. Advances in genetic research have identified causative mutations, facilitating the development of targeted therapeutic strategies. This shift from generalized immunosuppression to precision-based immunotherapy is transforming treatment paradigms [2]. The immune system consists of an intricate network of cells and molecules designed to recognize and eliminate pathogens while maintaining self-tolerance. In PIDs, genetic mutations disrupt these essential processes, leading to immune dysregulation [3] Depending on the affected immune component, PIDs can be classified into various categories, including defects in humoral immunity, cellular immunity, phagocytic function, and complement pathways [4] Recent advancements in next-generation sequencing have significantly improved the diagnosis of PIDs, allowing for early identification and intervention. Historically, treatment for PIDs has relied on broad-spectrum antibiotics, immunoglobulin replacement therapy, and hematopoietic stem cell transplantation [5] However, the discovery of specific genetic mutations has paved the way for more precise therapies, such as gene therapy and targeted biologics, which address the underlying cause of immune dysfunction [6] Monoclonal antibodies and small-molecule inhibitors are increasingly being utilized to modulate immune responses with greater specificity, reducing the risks associated with conventional immunosuppressive treatments [7] As research continues to elucidate the molecular mechanisms underlying PIDs, novel therapeutic strategies are being developed to optimize immune function while minimizing adverse effects. This review examines the pathophysiology of PIDs and explores emerging personalized immunotherapeutic approaches, including gene editing technologies and cytokine-based interventions, which hold promise for improving patient outcomes.

OPEN ACCESS
ONLINE ISSN: 2992-5460
PRINT ISSN: 2992-6041

Pathophysiology of Congenital Immune Defects

Congenital immune defects arise from genetic mutations affecting the development and function of key immune components [8] These mutations disrupt immune surveillance, pathogen elimination, and immune tolerance, resulting in increased susceptibility to infections, autoimmune disorders, and malignancies [9] Based on the affected pathway, primary immunodeficiency disorders (PIDs) are broadly classified into the following categories:

1. Defects in Innate Immunity

Innate immunity serves as the first line of defense, involving phagocytes, complement proteins, and pattern recognition receptors [10] Mutations affecting phagocytic function, complement pathways, or pattern recognition receptors compromise early immune responses. Chronic granulomatous disease (CGD) results from mutations in the NADPH oxidase complex, impairing pathogen killing by neutrophils and leading to recurrent bacterial and fungal infections [11] Complement deficiencies (e.g., C3, C5-C9 deficiencies) lead to defective opsonization and membrane attack complex formation, increasing susceptibility to encapsulated bacterial infections and Neisseria species.

2. Defects in Adaptive Immunity

Adaptive immunity relies on the coordinated function of B cells and T cells, which are critical for antigen-specific immune responses [12] Severe combined immunodeficiency (SCID) affects both T-cell and B-cell function due to mutations in IL2RG, ADA, or RAG genes, resulting in life-threatening infections early in infancy. X-linked agammaglobulinemia (XLA) results from BTK mutations, leading to absent B-cell development, impaired antibody production, and recurrent bacterial infections [13]. Common variable immunodeficiency (CVID) involves heterogeneous genetic defects impairing B-cell maturation and immunoglobulin production, resulting in hypogammaglobulinemia and recurrent sinopulmonary infections [14]

3. Disorders of Immune Regulation

Immune regulatory mechanisms prevent excessive immune activation and maintain self-tolerance. Autoimmune lymphoproliferative syndrome (ALPS) arises from FAS pathway mutations, leading to defective apoptosis of immune cells and excessive lymphocyte accumulation, predisposing to autoimmunity and lymphoma [15] Immune dysregulation, polyendocrinopathy, enteropathy, X-linked (IPEX) syndrome results from FOXP3 mutations, affecting regulatory T-cell function, leading to severe autoimmune manifestations such as type 1 diabetes, enteropathy, and dermatitis [16] As research advances, the identification of novel genetic defects continues to refine our understanding of PIDs, paving the way for more precise diagnostic and therapeutic strategies aimed at restoring immune function while minimizing disease complications.

Diagnostic Approaches

Accurate diagnosis of congenital immune defects is essential for guiding personalized immunotherapy [17] Key diagnostic strategies include genetic testing, flow cytometry, functional assays, and serological tests. Genetic testing, including whole exome sequencing (WES) and whole genome sequencing (WGS), helps identify causative mutations, enabling precise classification of primary immunodeficiency disorders [18] Flow cytometry is used for immunophenotyping to evaluate T-cell, B-cell, and NK-cell populations, providing insights into immune cell function and deficiencies. Functional assays assess specific immune activities, such as neutrophil oxidative burst for chronic granulomatous disease (CGD), complement function tests, and cytokine profiling to detect immune dysregulation [19] Serological tests measure immunoglobulin levels and vaccine-specific antibody responses, aiding in the diagnosis of humoral immune deficiencies. Advancements in next-generation sequencing and biomarker discovery continue to refine diagnostic accuracy, paving the way for earlier detection and targeted therapeutic interventions [20]

Personalized Immunotherapy Strategies

The evolution of precision medicine has led to innovative immunotherapeutic strategies tailored to specific genetic defects in PIDs.

1. Gene Therapy

Gene-editing techniques such as CRISPR-Cas9 and lentiviral vector-based gene addition have revolutionized treatment for SCID, CGD, and WAS (Wiskott-Aldrich syndrome). Ex vivo gene correction in autologous hematopoietic stem cells (HSCs) offers durable immune reconstitution with reduced graft-versus-host disease (GVHD) risk [21]

2. Monoclonal Antibody Therapy

Rituximab (anti-CD20) is used in CVID patients with B-cell dysregulation and autoimmune complications. Eculizumab (anti-C5) is indicated for complement deficiencies leading to recurrent Neisseria infections [22]

3. Cytokine Modulation

IFN-gamma therapy enhances macrophage activation in CGD. IL-2 and IL-7 therapies are explored for enhancing T-cell function in immunodeficient patients [23]

OPEN ACCESS
ONLINE ISSN: 2992-5460
PRINT ISSN: 2992-6041

4. Hematopoietic Stem Cell Transplantation (HSCT)

HSCT remains the standard curative therapy for SCID and other severe PIDs. Reduced-intensity conditioning (RIC) regimens are being optimized to minimize transplant-related toxicity [24]

Challenges and Future Directions

Despite significant advances, several challenges remain in the field of personalized immunotherapy for congenital immune defects. Genetic heterogeneity remains a major hurdle, as identifying and targeting diverse genetic mutations across different patient populations complicates the development of universal therapeutic strategies [25]. Many primary immunodeficiency disorders (PIDs) result from a spectrum of mutations within the same gene, necessitating tailored approaches for different genetic variants [26]. Long-term safety is another critical concern. Gene-editing technologies, including CRISPR-Cas9, hold great promise, but the potential for off-target effects and unintended genomic alterations must be carefully assessed. Longitudinal studies are required to evaluate the durability of gene therapy outcomes and the risk of adverse effects, such as malignancy or immune dysregulation [27]. Access to therapy remains a significant barrier, particularly in resource-limited settings. While hematopoietic stem cell transplantation (HSCT) and gene therapy offer curative potential, their high costs and the need for specialized medical infrastructure limit their widespread implementation [28] Expanding the availability of these therapies through global health initiatives and innovative funding mechanisms is essential to ensure equitable access. Monitoring immune reconstitution post-therapy is crucial for assessing treatment success and guiding further interventions. Current methods rely on immunophenotyping, cytokine profiling, and functional immune assays, but more robust and predictive biomarkers are needed. Advances in single-cell sequencing and multi-omics approaches may provide deeper insights into immune recovery and disease progression.

CONCLUSION

Congenital immune defects represent a major area of research in immunology and precision medicine. Advances in genetic diagnostics and targeted immunotherapy have transformed the management of PIDs, enabling personalized treatment approaches that improve survival and quality of life. Gene therapy, monoclonal antibodies, and cytokine modulation have opened new avenues for disease management, while HSCT remains a cornerstone for severe cases. Ongoing research into novel gene therapies, immune modulation, and transplantation techniques holds the potential to further revolutionize care for patients with congenital immune deficiencies. Future efforts should focus on expanding access to these therapies, refining gene-editing precision, and optimizing long-term outcomes through individualized treatment strategies. A multidisciplinary approach integrating genetics, immunology, and bioinformatics will be key to overcoming current challenges and advancing the field toward more effective and accessible therapies.

REFERENCES

1. Jung S, Gies V, Korganow AS, Guffroy A. Primary Immunodeficiencies with Defects in Innate Immunity: Focus on Orofacial Manifestations. Front Immunol. 2020; 11:1065. doi: 10.3389/fimmu.2020.01065. PMID: 32625202; PMCID: PMC7314950.
2. Raje N, Dinakar C. Overview of Immunodeficiency Disorders. Immunol Allergy Clin North Am. 2015; 35(4):599-623. doi: 10.1016/j.iac.2015.07.001. Epub 2015 Aug 25. PMID: 26454309; PMCID: PMC4600970.
3. Pessach, I., Walter, J. & Notarangelo, L. Recent Advances in Primary Immunodeficiencies: Identification of Novel Genetic Defects and Unanticipated Phenotypes. *Pediatr Res.*, 2009; **65**, 3–12. https://doi.org/10.1203/PDR.0b013e31819dbe1e
4. Kim, V.H.D., Upton, J.E.M., Derfalvi, B. *et al.* Inborn errors of immunity (primary immunodeficiencies). *Allergy Asthma Clin Immunol.*, 2024; **20** (Suppl 3), 76. https://doi.org/10.1186/s13223-024-00938-z
5. Edeer Karaca N. Neutropenia in Primary Immunodeficiency Diseases [Internet]. Innate Immunity in Health and Disease. IntechOpen; 2021. Available from: http://dx.doi.org/10.5772/intechopen.97297
6. George K, Govindaraj G. Infections in Inborn Errors of Immunity with Combined Immune Deficiency: A Review. *Pathogens.* 2023; 12(2):272. https://doi.org/10.3390/pathogens12020272
7. Flinn, A.M., Gennery, A.R. Primary immune regulatory disorders: Undiagnosed needles in the haystack?. *Orphanet J Rare Dis.*, 2022; **17**, 99. https://doi.org/10.1186/s13023-022-02249-1
8. Janeway CA Jr, Travers P, Walport M, et al. Immunobiology: The Immune System in Health and Disease. 5th edition. New York: Garland Science; 2001. Inherited immunodeficiency diseases. Available from: https://www.ncbi.nlm.nih.gov/books/NBK27109/
9. Pessach, I., Walter, J. & Notarangelo, L. Recent Advances in Primary Immunodeficiencies: Identification of Novel Genetic Defects and Unanticipated Phenotypes. *Pediatr Res.*, 2009; **65**, 3–12. https://doi.org/10.1203/PDR.0b013e31819dbe1e

OPEN ACCESS
ONLINE ISSN: 2992-5460
PRINT ISSN: 2992-6041

10. Napiórkowska-Baran K, Darwish S, Kaczor J, Treichel P, Szymczak B, Szota M, Koperska K, Bartuzi Z. Oral Diseases as a Manifestation of Inborn Errors of Immunity. *Journal of Clinical Medicine*. 2024; 13(17):5079. https://doi.org/10.3390/jcm13175079
11. Redmond, M.T., Scherzer, R. & Prince, B.T. Novel Genetic Discoveries in Primary Immunodeficiency Disorders. *Clinic Rev Allerg Immunol.*, 2022; **63**, 55–74. https://doi.org/10.1007/s12016-021-08881-2
12. Alberts B, Johnson A, Lewis J, et al. Molecular Biology of the Cell. 4th edition. New York: Garland Science; 2002. Chapter 24, The Adaptive Immune System. Available from: https://www.ncbi.nlm.nih.gov/books/NBK21070/
13. Marshall, J.S., Warrington, R., Watson, W. *et al.* An introduction to immunology and immunopathology. *Allergy Asthma Clin Immunol.*, 2018; **14** (Suppl 2), 49. https://doi.org/10.1186/s13223-018-0278-1
14. Li, Y., Wang, W., Yang, F. *et al.* The regulatory roles of neutrophils in adaptive immunity. *Cell Commun Signal.*, 2019; **17**, 147. https://doi.org/10.1186/s12964-019-0471-y
15. Sun, L., Su, Y., Jiao, A. *et al.* T cells in health and disease. *Sig Transduct Target Ther.*, 2023; **8**, 235. https://doi.org/10.1038/s41392-023-01471-y
16. Pollard, A.J., Bijker, E.M. A guide to vaccinology: from basic principles to new developments. *Nat Rev Immunol.*, 2021; **21**, 83–100. https://doi.org/10.1038/s41577-020-00479-7
17. Oliveira JB, Fleisher TA. Laboratory evaluation of primary immunodeficiencies. J Allergy Clin Immunol. 2010; 125(2 Suppl 2):S297-305. doi: 10.1016/j.jaci.2009.08.043. Epub 2009 Dec 29. PMID: 20042230; PMCID: PMC3412511.
18. Varadé J, Magadán S, González-Fernández Á. Human immunology and immunotherapy: main achievements and challenges. Cell Mol Immunol. 2021; 18(4):805-828. doi: 10.1038/s41423-020-00530-6.
19. Chen R. Primary Immunodeficiency [Internet]. Rare Diseases. IntechOpen; 2020. Available from: http://dx.doi.org/10.5772/intechopen.89624
20. Perez E, Bonilla FA, Orange JS, Ballow M. Specific Antibody Deficiency: Controversies in Diagnosis and Management. Front Immunol. 2017; 8:586. doi: 10.3389/fimmu.2017.00586.
21. Parker AR, Skold M, Ramsden DB, Ocejo-Vinyals JG, López-Hoyos M, Harding S. The Clinical Utility of Measuring IgG Subclass Immunoglobulins During Immunological Investigation for Suspected Primary Antibody Deficiencies. Lab Med. 2017; 48(4):314-325. doi: 10.1093/labmed/lmx058. PMID: 29126302; PMCID: PMC5907904.
22. Bonanni P, Cantón R, Gill D, Halfon P, Liebert UG, Crespo KAN, Martín JJP, Trombetta CM. The Role of Serology Testing to Strengthen Vaccination Initiatives and Policies for COVID-19 in Europe. *COVID.* 2021; 1(1):20-38. https://doi.org/10.3390/covid1010004
23. Miller CH, Maher SG, Young HA. Clinical Use of Interferon-gamma. Ann N Y Acad Sci. 2009; 1182:69-79. doi: 10.1111/j.1749-6632.2009.05069.x. PMID: 20074276; PMCID: PMC6574079.
24. Wu, Y., Sun, X., Kang, K. *et al.* Hemophagocytic lymphohistiocytosis: current treatment advances, emerging targeted therapy and underlying mechanisms. *J Hematol Oncol.*, 2024; **17**, 106. https://doi.org/10.1186/s13045-024-01621-x
25. Al, B., Bruno, M., Röring, R.J. *et al.* Peripheral T Cell Populations are Differentially Affected in Familial Mediterranean Fever, Chronic Granulomatous Disease, and Gout. *J Clin Immunol.*, 2023; **43**, 2033–2048. https://doi.org/10.1007/s10875-023-01576-7
26. Guo C, Ma X, Gao F, Guo Y. Off-target effects in CRISPR/Cas9 gene editing. Front Bioeng Biotechnol. 2023; 11:1143157. doi: 10.3389/fbioe.2023.1143157. PMID: 36970624; PMCID: PMC10034092.
27. Lopes R, Prasad MK. Beyond the promise: evaluating and mitigating off-target effects in CRISPR gene editing for safer therapeutics. Front Bioeng Biotechnol. 2024; 11:1339189. doi: 10.3389/fbioe.2023.1339189. PMID: 38390600; PMCID: PMC10883050.
28. Chehelgerdi, M., Chehelgerdi, M., Khorramian-Ghahfarokhi, M. *et al.* Comprehensive review of CRISPR-based gene editing: mechanisms, challenges, and applications in cancer therapy. *Mol Cancer.*, 2024; **23**, 9. https://doi.org/10.1186/s12943-023-01925-5

CITE AS: Nakaziya Obutuzi G. (2025). Congenital Defects in the Immune System: A Pathway to Personalized Immunotherapy. Newport International Journal of Research in Medical Sciences, 6(2):11-14 https://doi.org/10.59298/NIJRMS/2025/6.2.1114